Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593227 · ClinicalTrials.gov registry record · Phase 2
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Marker Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT02593227 is a Phase 2 study of Breast Cancer that has completed, run by Marker Therapeutics. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT02593227, a Phase 2 study of Breast Cancer, has completed, sponsored by Marker Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Low dose FRα vaccine
- BIOLOGICAL High dose FRα vaccine
Study Locations (11)
New York
- Mount Sinai Hospital - New York
- Montefiore Medical Center, Einstein Cancer Center - New York
Florida
- Moffitt Cancer Center - Tampa
Kansas
- University of Kansas Cancer Center - Westwood
Maryland
- University of Maryland - Greenebaum Cancer Center - Baltimore
Michigan
- Karmanos Cancer Center - Detroit
Missouri
- MidAmerica Division,Inc - Kansas City
New Jersey
- The Valley Hospital - Paramus
Ohio
- Oncology Hematology Care - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593227
The ClinicalTrials.gov registry entry for NCT02593227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02593227 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT02593227 about?
NCT02593227 is a clinical study titled "Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer". This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients ...
What is the current status of trial NCT02593227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-04. Estimated completion is 2021-07-15.
What conditions does trial NCT02593227 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02593227?
The interventions under investigation include: Cyclophosphamide (DRUG), Low dose FRα vaccine (BIOLOGICAL), High dose FRα vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593227?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593227 being conducted?
This trial has 11 study locations across Florida, Kansas, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.